Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122649 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1HPGDKLK7CES1 | |
| SCHEMBL1123239 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1HPGDKLK7CES1 | |
| SCHEMBL8473555 | 0.78 | S100A4 (0.35) | ALDH1A1HPGDCES1HTR2CHTT | |
| SCHEMBL9740397 | 0.75 | HTR2C (0.32) | HTR2C | |
| SCHEMBL8793891 | 0.73 | KMT2A (0.31) | KMT2A | |
| SCHEMBL9522438 | 0.71 | GSK3B (0.43) | KDM4EALDH1A1HPGDGSK3BKMT2A | |
| SCHEMBL8794212 | 0.70 | HTT (0.32) | KDM4EALDH1A1HTR2CHTT | |
| SCHEMBL3927087 | 0.70 | HTR2C (0.34) | KDM4EALDH1A1HTR2C | |
| SCHEMBL15606100 | 0.69 | HTR2C (0.39) | KDM4EALDH1A1HPGDCES1HTR2C | |
| SCHEMBL16886968 | 0.69 | HTR2C (0.39) | KDM4EALDH1A1HPGDCES1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | claimed |
| EP-2128161-A1 | Process for obtaining 4-hydroxy-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-7,7-dioxide and its enantiomers, and applications thereof | Ragactives, S.L. (ES) | 2009-12-02 | — | — | EP | claimed |
| US-8263787-B2 | Process for preparing dorzolamide | CIPLA LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| US-8263787-B2 | Process for preparing dorzolamide | CIPLA LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| WO-2011101704-A1 | PROCESS FOR PREPARING (4S, 6S)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO-[2,3-B]THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE AND ITS INTERMEDIATES | MICRO LABS LIMITED (IN) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113804-A1 | Process for Preparing Dorzolamide | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113804-A1 | Process for Preparing Dorzolamide | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| WO-2009144263-A2 | PROCESS FOR OBTAINING 4-HYDROXY-6-METHYL-5, 6-DIHYDRO-4H-THIENO [2,3-b] THIOPYRAN-7, 7-DIOXIDE AND ITS ENANTIOMERS, AND APPLICATIONS THEREOF | RAGACTIVES, S.L.U. (ES) | 2009-12-03 | — | — | WO | disclosed |
| EP-2128161-A1 | Process for obtaining 4-hydroxy-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-7,7-dioxide and its enantiomers, and applications thereof | Ragactives, S.L. (ES) | 2009-12-02 | — | — | EP | disclosed |
| EP-2128161-A1 | Process for obtaining 4-hydroxy-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-7,7-dioxide and its enantiomers, and applications thereof | Ragactives, S.L. (ES) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008135770-A2 | PROCESS FOR PREPARING DORZOLAM IDE | CIPLA LIMITED (IN) | 2008-11-13 | — | — | WO | disclosed |
| EP-0296879-B1 | SUBSTITUTED AROMATIC SULFONAMIDES AS ANTIGLAUCOMA AGENTS | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4863922-A | Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use | MERCK & CO., INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0296879-A1 | Substituted aromatic sulfonamides as antiglaucoma agents | MERCK & CO. INC. (US) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113804-A1 | Process for Preparing Dorzolamide | SQOR, PPOX, DAO | KDM4E 2357/4885ALDH1A1 275/4885HPGD 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.